Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Booster Dose Study of MVC-COV1901, AZD1222, and mRNA-1273
NCT05197153Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Medigen Biotechnology. Started Jan 2022; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05197153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197153.